Bionoid Pharma, Inc. Provides Corporate Update and Outlines Growth Strategy for 2025
-
Australian announces gun buyback, day of 'reflection' after Bondi shooting
-
Joshua takes huge weight advantage into Paul fight
-
TikTok signs joint venture deal to end US ban threat
-
Conway's glorious 200 powers New Zealand to 424-3 against West Indies
-
WNBA lockout looms closer after player vote authorizes strike
-
Honduras begins partial vote recount in Trump-dominated election
-
Nike shares slump as China struggles continue
-
Hundreds swim, float at Bondi Beach to honour shooting victims
-
Crunch time for EU leaders on tapping Russian assets for Ukraine
-
Pope replaces New York's pro-Trump Cardinal with pro-migrant Chicagoan
-
Trump orders marijuana reclassified as less dangerous drug
-
Rams ace Nacua apologizes over 'antisemitic' gesture furor
-
McIlroy wins BBC sports personality award for 2025 heroics
-
Napoli beat Milan in Italian Super Cup semi-final
-
Violence erupts in Bangladesh after wounded youth leader dies
-
EU-Mercosur deal delayed as farmers stage Brussels show of force
-
US hosting new Gaza talks to push next phase of deal
-
Chicago Bears mulling Indiana home over public funding standoff
-
Trump renames Kennedy arts center after himself
-
Trump rebrands housing supplement as $1,776 bonuses for US troops
-
Harrison Ford to get lifetime acting award
-
Trump health chief seeks to bar trans youth from gender-affirming care
-
Argentine unions in the street over Milei labor reforms
-
Trump signs order reclassifying marijuana as less dangerous
-
Famed Kennedy arts center to be renamed 'Trump-Kennedy Center'
-
US accuses S.Africa of harassing US officials working with Afrikaners
-
Brazil open to EU-Mercosur deal delay as farmers protest in Brussels
-
Wounded Bangladesh youth leader dies in Singapore hospital
-
New photo dump fuels Capitol Hill push on Epstein files release
-
Brazil, Mexico seek to defuse US-Venezuela crisis
-
Assange files complaint against Nobel Foundation over Machado win
-
Private donors pledge $1 bn for CERN particle accelerator
-
Russian court orders Austrian bank Raiffeisen to pay compensation
-
US, Qatar, Turkey, Egypt to hold Gaza talks in Miami
-
Lula open to mediate between US, Venezuela to 'avoid armed conflict'
-
Brussels farmer protest turns ugly as EU-Mercosur deal teeters
-
US imposes sanctions on two more ICC judges for Israel probe
-
US accuses S. Africa of harassing US officials working with Afrikaners
-
ECB holds rates as Lagarde stresses heightened uncertainty
-
Trump Media announces merger with fusion power company
-
Stocks rise as US inflation cools, tech stocks bounce
-
Zelensky presses EU to tap Russian assets at crunch summit
-
Pope replaces New York's Cardinal Dolan with pro-migrant bishop
-
Odermatt takes foggy downhill for 50th World Cup win
-
France exonerates women convicted over abortions before legalisation
-
UK teachers to tackle misogyny in classroom
-
Historic Afghan cinema torn down for a mall
-
US consumer inflation cools unexpectedly in November
-
Danish 'ghetto' residents upbeat after EU court ruling
-
ECB holds rates but debate swirls over future
NYSE - LSE
Bionoid Pharma, Inc. Provides Corporate Update and Outlines Growth Strategy for 2025
Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is pleased to provide a corporate update as it looks ahead to a promising year in 2025. The company remains committed to its strategic growth plan, which centers on acquiring revenue-positive e-commerce websites and integrating advanced AI technology to drive expansion in the health and wellness sector.
Bionoid's proprietary AI Maverick Intel platform will play a pivotal role in the company's growth strategy. This cutting-edge AI-driven marketing system is designed to enhance customer engagement, optimize advertising efficiency, and deliver tailored user experiences. By leveraging AI Maverick Intel, Bionoid aims to maximize the potential of its e-commerce platforms and solidify its position as an innovator in the industry.
"Our vision for 2025 is focused on scaling our operations through strategic acquisitions and harnessing the power of AI technology," said Wayne Cockburn, CEO of Bionoid Pharma, Inc. "AI Maverick Intel is a cornerstone of our strategy, enabling us to deliver unparalleled customer experiences while driving sustainable growth and profitability."
Bionoid plans to expand its portfolio with high-value, revenue-generating e-commerce websites in the health and wellness sector, ensuring each acquisition aligns with its long-term objectives. The company is confident its continued focus on innovation and strategic execution will deliver strong results for its stakeholders in the coming year.
About Bionoid Pharma, Inc.
Bionoid Pharma, Inc. is a forward-thinking health and wellness company dedicated to expanding its revenue streams and brand presence through strategic acquisitions and advanced AI technology. Its proprietary AI Maverick platform supports the company's mission to deliver innovative, AI-driven solutions that foster customer loyalty, operational excellence, and sustainable growth.
Stay connected:
Website: BionoidPhama.com
OTC Markets: BINP
For further information, contact:
Wayne Cockburn, CEO
Phone: (905) 505-0770
Email: [email protected]
SOURCE: Bionoid Pharma, Inc.
O.Norris--AMWN
